Dexamethasone intravitreal implant for treatment of persistent macular oedema in Birdshot retinochoroidopathy

2016 ◽  
Vol 91 (3) ◽  
pp. 138-141
Author(s):  
P. Rivera de Zea ◽  
A. García-Ben ◽  
N. Rachwani Parshotam ◽  
J.M. García-Campos
Keyword(s):  
Macular Oedema ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant

scholarly journals Dexamethasone intravitreal implant in treatment-naïve diabetic macular oedema: findings from the prospective, multicentre, AUSSIEDEX study

2021 ◽  
pp. bjophthalmol-2021-319070
Author(s):  
Samantha Fraser-Bell ◽  
Hyong Kwon Kang ◽  
Paul Mitchell ◽  
Jennifer J Arnold ◽  
Jodi Tainton ◽  
...  
Keyword(s):  
Real World ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Common Adverse Event ◽  
Open Label ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant ◽  
Registration Number ◽  
Treatment Naïve ◽  
Change In Mean

AimTo evaluate the effectiveness of dexamethasone intravitreal implant 0.7 mg (DEX; Ozurdex) monotherapy in the patient subgroup of the AUSSIEDEX study with treatment-naïve diabetic macular oedema (DME).MethodsThe open-label, prospective, phase 4, real-world study included pseudophakic eyes and phakic eyes scheduled for cataract surgery that were treatment-naïve or non-responsive to antivascular endothelial growth factors. No eyes were excluded based on baseline best-corrected visual acuity (BCVA) or central subfield retinal thickness (CRT). After the initial DEX injection at the baseline visit, reinjection was permitted at ≥16-week intervals. Week-16 and week-52 visits were mandatory. Primary endpoints were changes in mean BCVA and CRT from baseline to 52 weeks.ResultsOf 200 eyes enrolled in the AUSSIEDEX study, 57 were treatment-naïve. Baseline mean BCVA was 58.8 letters and baseline mean CRT was 418.6 µm; changes in mean BCVA and CRT from baseline to 52 weeks in this subgroup were 3.4 letters (p=0.042) and –89.6 µm (p<0.001), respectively, with a mean 2.5 injections. The change in mean CRT from baseline was –55.8 µm at week 16 (p<0.001). The most common adverse event was increased intraocular pressure (IOP), with 20.0% of eyes requiring IOP-lowering medication. One patient was discontinued due to increased IOP. No eyes required filtration surgery. No serious, treatment-related ocular adverse events were reported.ConclusionIn this largest prospective, real-world study of DEX monotherapy for DME to date, DEX significantly improved CRT and BCVA at 52 weeks in treatment-naïve eyes, without new safety concerns, supporting DEX use in treatment-naïve DME.Trial registration numberNCT02731911.

Phacoemulsification and dexamethasone intravitreal implant in diabetic patients: A combined approach

2021 ◽  
pp. 112067212110393
Author(s):  
Lucrezia Montrone ◽  
Giancarlo Macinagrossa
Keyword(s):  
Macular Oedema ◽  
Functional Outcomes ◽  
Diabetic Macular Oedema ◽  
Diabetic Patients ◽  
Foveal Thickness ◽  
Systemic Complications ◽  
Dexamethasone Intravitreal Implant ◽  
Intravitreal Implant ◽  
Lens Surgery

Purpose: To analyse the morpho-functional outcomes of dexamethasone intravitreal implant (Ozurdex) injected after lens surgery in diabetic patients with coexisting cataract and macular oedema. Methods: This is a non-randomized, perspective, single-group study on 17 eyes with a diagnosis of cataract and early and advanced diabetic macular oedema. All eyes underwent combined phacoemulsification and Ozurdex injection at the end of surgery and morpho-functional outcomes were analysed in 3 months follow-up. Results: Foveal thickness decreased significantly from 349.6 ± 19.8 (95% CI) at baseline to 310.7 ± 17.5 (95% CI) 90 days after surgery ( p < 0.01). Mean BCVA (LogMAR) improved significantly from 0.38 ± 0.08 (95% CI) at baseline to 0.15 ± 0.06 (95% CI) after 90 days ( p < 0.01). Any ocular or systemic complications were observed during follow-up. Conclusions: Dexamethasone intravitreal implant combined with phacoemulsification may be safe and effective to improve morpho-functional outcomes in diabetic patients with coexisting cataract and macular oedema.

scholarly journals Retrospective, Observational Study in Patients Receiving a Dexamethasone Intravitreal Implant 0.7 mg for Macular Oedema Secondary to Retinal Vein Occlusion

2014 ◽  
Vol 233 (1) ◽  
pp. 18-26 ◽  
Author(s):  
Albert J. Augustin ◽  
Frank G. Holz ◽  
Christos Haritoglou ◽  
Wolfgang J. Mayer ◽  
Silvia Bopp ◽  
...  
Keyword(s):  
Observational Study ◽  
Retinal Vein Occlusion ◽  
Macular Oedema ◽  
Routine Practice ◽  
Glaucoma Medication ◽  
Dexamethasone Intravitreal Implant ◽  
Vein Occlusion ◽  
Intravitreal Implant ◽  
Injection Interval ◽  
Mean Time

Purpose: To retrospectively evaluate the re-injection interval, efficacy and safety of dexamethasone (DEX) intravitreal implant 0.7 mg in the treatment of macular oedema (ME) due to retinal vein occlusion (RVO) in Germany in 2009-2012. Methods: Retrospective, multicentre, anonymised observational study of data collected from the first DEX implant 0.7 mg injection through 3-6 months following the last injection. Data were included if the patient was >18 years old, had a diagnosis of ME secondary to branch or central RVO, and received at least 2 DEX implant 0.7 mg injections during routine practice. Results: Data from 87 patients were analysed. Mean time to re-injection between first and second treatments was 5.03 months in the total RVO population, and 5.46 and 4.52 months for the branch and central RVO subpopulations, respectively. An intraocular pressure increase of >25 mm Hg was recorded in 20% of patients, and 34% of patients began treatment with anti-glaucoma medication, but surgery was not needed for this condition. Conclusions: DEX implant 0.7 mg was found to be well tolerated and effective with repeat treatments in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document